TY - JOUR
T1 - Brief report
T2 - Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)
AU - Moorman, Anthony V.
AU - Richards, Susan M.
AU - Robinson, Hazel M.
AU - Strefford, Jon C.
AU - Gibson, Brenda E.S.
AU - Kinsey, Sally E.
AU - Eden, Tim O.B.
AU - Vora, Ajay J.
AU - Mitchell, Christopher D.
AU - Harrison, Christine J.
PY - 2007/3/15
Y1 - 2007/3/15
N2 - Patients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.
AB - Patients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.
UR - http://www.scopus.com/inward/record.url?scp=33947257508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947257508&partnerID=8YFLogxK
U2 - 10.1182/blood-2006-08-040436
DO - 10.1182/blood-2006-08-040436
M3 - Article
C2 - 17095619
AN - SCOPUS:33947257508
SN - 0006-4971
VL - 109
SP - 2327
EP - 2330
JO - Blood
JF - Blood
IS - 6
ER -